Research programme: progesterone antagonists - Ligand/Wyeth

Drug Profile

Research programme: progesterone antagonists - Ligand/Wyeth

Alternative Names: LG 1127; LG 1447; Progesterone antagonists research programme - Ligand/Wyeth; WAY 160248; WAY-075

Latest Information Update: 10 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Class
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Endometriosis; Female genital diseases; Pregnancy; Uterine leiomyoma

Most Recent Events

  • 10 Aug 2009 Discontinued - Preclinical for Gynaecological disorders in USA (unspecified route)
  • 10 Aug 2009 Discontinued - Preclinical for Pregnancy (Prevention) in USA (PO)
  • 23 Jun 2004 This programme is still in active development - [(BIO 2004 Annual International Convention (BIO-2004)]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top